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Abstract
Background: Uveal Melanoma is a rare tumour that dis-
plays different clinical behavior and molecular features 
compared with cutaneous melanoma. It is generally resis-
tant to systemic therapy and there is no current standard 
effective therapy to treat patients with advanced disease.
Patients and methods: We searched Medline, PubMed, 
EMBASE and major oncology conference abstracts from the 
past 5 years to identify relevant studies evaluating ipilimumab 
monotherapy in uveal melanoma. Data were extracted on ipili-
mumab dose, sample size, Objective Response Rate (ORR), 
Progression Free Survival (PFS), median Overall Survival 
(mOS), Disease Control Rate (DCR), 1 year Overall Survival 
(1yrOS) and 2 year Overall Survival (2yrOS).
Results: Nine studies were included in this study including 
Phase II clinical trials (n = 2), Expanded Access Programs 
(EAP) (n = 4) and retrospective studies (n = 3). Cases were 
a mix of pre-treated and treatment-naïve patients.  Report-
ed mOS ranged from 5.2-28 months (median: 9.3 months), 
and reported 1yrOS ranged between 4.5-65%. Calculated 
compound ORR was 3.4%, and compound DCR was 36%. 
Conclusion: Ipilimumab has limited clinical activity in ad-
vanced uveal melanoma. Further research is needed to 
identify more effective systemic therapies for management 
of these patients.
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per million people [1]. It accounts for less than 5% of all 
melanoma cases [2]. UM arises from the vascular layers 
of the eye (iris, ciliary body, and choroid). It is a highly 
aggressive malignancy and about 50% of patients will 
develop metastatic disease at some stage after prior 
diagnosis of primary uveal melanoma [3]. Liver is the 
dominant site of metastases (60-90%) followed by lungs 
(25%) [4,5]. Prognosis in advanced disease is poor, with 
median overall survival ranging between 2-15 months 
[5-7].
UM has a distinct molecular profile, and displays 
different clinical behavior to cutaneous melanoma. In 
contrast to BRAF and NRAS mutations commonly seen 
in cutaneous melanoma, mutations in heterotrimeric G 
protein-α (GNA) subunits GNAQ and GNA11 have been 
reported in up to 80% of uveal melanomas [8].
Treatment options for UM are particularly limited 
and efficacy data is scarce [9]. There are a few small 
studies that describe options such as chemotherapy, 
metastasectomy, and hepatic intra-arterial chemoem-
bolization [10]. Response rates are dismal [9], with one 
retrospective review reporting response rates to sys-
temic treatment being as low as 1% [3].
Immunotherapy has revolutionized the treatment 
landscape for metastatic melanoma in the last 5 years. 
Ipilimumab is a fully humanized monoclonal antibody 
that blocks the Cytotoxic T-Lymphocyte-Associated An-
tigen 4 (CTLA-4), promoting anti-tumour immunity. It is 
routinely used in metastatic melanoma, and was one 
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Introduction
Uveal Melanoma (UM) is a rare tumour, with an esti-
mated annual global incidence between 5.3-10.9 cases 
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of the first treatment to ever demonstrate a survival 
benefit in large randomized trial in advanced melanoma 
[11,12]. However, most of the studies examining activi-
ty of ipilimumab in advanced melanoma have tradition-
ally excluded patients with uveal melanoma [11,12].
The aim of this paper was to conduct pool analysis 
of published literature, evaluating the efficacy of ipili-
mumab monotherapy in the management of advanced 
uveal melanoma.
Patients and Methods
This review was conducted in accordance with the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines [13].
MEDLINE, PubMed and EMBASE search was con-
ducted to identify relevant articles, with no restrictions 
placed on the search. All published prospective and ret-
rospective studies, examining ipilimumimab activity in 
advanced uveal melanoma, amongst both pre-treated 
and treatment-naïve patients were included. Relevant 
abstracts from the American Society of Clinical Oncol-
ogy (ASCO) and European Society of Medical Oncolo-
gy (ESMO) annual scientific meetings presented in the 
last 5 years were also evaluated. We used the following 
search terms: “Uveal melanoma” and “ipilimumab”, in 
any combination in the titles of published trials or con-
ference abstracts. Initial search results were screened 
for duplication and relevance. The full articles and ab-
stracts were then reviewed in detail. Data were manu-
ally extracted on study design, ipilimumab dose, sample 
size, Objective Response Rate (ORR), Progression Free 
Survival (PFS), Overall Survival (OS), Disease Control 
Rate (DCR), 1 year Overall Survival (1yrOS) and 2 year 
Overall Survival (2yrOS). Note was made of any limita-
tions and bias present in individual studies.
Our primary endpoints were median Overall Survival 
(mOS) and percentage 1 year Overall Survival (1yrOS). 
Secondary endpoints included Objective Response Rate 
(ORR), Disease Control Rate (DCR) and median Progres-
sion Free Survival (mPFS).
Due to wide variation in study design and reported out-
comes, key efficacy endpoints from each individual trial 
were summarized. Forest plots were constructed to de-
pict and compare PFS and OS, along with 95% Confidence 
Intervals (95% CI) for each trial where relevant data was 
available. Pooled data was used to calculate compound 
ORR and DCR using a random distribution model.
Results
The identification and screening process as per PRIM-
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Figure 1: Study Identification, Screening and Inclusion process (PRISMA flow chart).
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in addition to fatigue and fever. Grade 3 or 4 irAEs oc-
curred in 10-33% of cases. IrAE’s were generally revers-
ible when managed as per protocol-specific guidelines. 
No new safety signals were seen compared to original 
ipilimumab phase 3 studies.
Discussion
Uveal Melanoma is a rare and highly aggressive tu-
SA guidelines is depicted in Figure 1. Nine articles were 
included in this study; including Phase II clinical trials (n 
= 2), Expanded Access Programs (EAP) (n = 4) and retro-
spective studies (n = 3) [14-22]. The key features of each 
trial are summarized in Table 1.
The reported median patient age ranged from 42-67 
years. Ipilimumab was prescribed at either a high induc-
tion dose (10 mg/kg) or standard dose (3 mg/kg). Reported 
mOS ranged from 5.2-28 months, with an overall median 
of 9.3 months (mean of 9.1 months) (Figure 2). Progres-
sion free survival data was limited and ranged from 2.8-
3.6 (Figure 3). Median PFS could not be calculated for the 
reported studies as relevant data was not published or not 
provided. The 1yr OS ranged between 4.5-65% (Figure 4). 
Calculated compound ORR was 3.4% and compound DCR 
was 36%.
Eight studies included a toxicity analysis, with im-
mune related adverse effects (irAEs) graded according 
to common toxicity criteria. Common irAEs included 
rash, itch, diarrhea/colitis, hepatitis, and hypophysitis, 
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Figure 2: Forest plot of median Overall Survival (OS) from 
included trials.
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Figure 3: Forest plot of progression free survival from included 
trials.
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Figure 4: Survival % at 1 and 2 years for reported trials.
Table 1: Summary of trials included in meta-analysis.
Study Design N Ipi dose 
(mg/kg)
Pre-treated ORR% DCR% mPFS mOS 1yr OS% 2yr OS%
Zimmer [15] Phase II 53 3 Mixed 0 47 2.8
(2.5-2.9)
6.8
(3.7-8.1)
22
(12-35)
7
(1-18)
Rodriguez [16] Phase II 32 10 Rx Naive 6.4
(0.79-21.4)
45.1 NR NR 48.4
(33.6-69.6)
24.6
(12.6-47.8)
Deo [14] Retro 24 3 Pre-Rx 4 21 2.8 9.7 45.6 11.4
Maio [17] EAP 82 3 Pre-Rx 5 34 3.6
(2.8-4.4)
6
(4.3-7.7)
31 NR
Khattak [18] EAP 5 3 Pre-Rx 0 40 NR 10.3
(2.4-20.6)
40 NR
Luke [19] Retro 39 3/10 Mixed 2.6 46.1 NR 9.6
(6.3-13.4)
NR NR
Kelderman [20] EAP 22 3 Pre-Rx 4.5 9 2.9
(2.3-5.3)
5.2
(4.9-9.6)
4.5 NR
Danielli [21] EAP 13 10 Pre-Rx 0 23 NR 9
(0.5-43)
NR NR
Moser [22] NR 23 NR Pre-Rx NR NR NR 28m
(12-38)
65 NR
NR: Not Reported; ORR: Objective Response Rate; PFS: Progression Free Survival; OS: Overall Survival; DCR: Disease Control Rate.
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intervals not reported in several studies. We were un-
able to retrieve more complete data by contacting the 
primary investigators despite our efforts to do so. Sam-
ple size in all these studies is relatively small and most 
are retrospective. It is possible that the inclusion of re-
sults from EAPs predisposes investigators to a positive 
publication bias.
Conclusion
Despite the limitations of the published data, we 
think there is reasonable evidence to suggest that ip-
ilimumab has modest clinical activity and manageable 
toxicity when used in the treatment of advanced UM 
in the absence of any other suitable systemic therapy 
options. Future studies should explore newer immuno-
therapies and targeted therapies either as monothera-
py or in combination.
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